Eckert & Ziegler SE (WBO:EUZG) Beta: N/A (As of Jun. 26, 2026)


WBO:EUZG Eckert & Ziegler SE WBO:EUZG
79 GF Score
Price €15.32
GF Value €16.21
Valuation Fairly Valued
View Full Analysis

What is Eckert & Ziegler SE Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Eckert & Ziegler SE's Beta is Not available.

Eckert & Ziegler SE  (WBO:EUZG) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Eckert & Ziegler SE Beta Related Terms

Eckert & Ziegler SE Beta Historical Data

* Premium members only.

The historical data trend for Eckert & Ziegler SE's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eckert & Ziegler SE Beta Chart

Eckert & Ziegler SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eckert & Ziegler SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:EUZG
79GF Score
Eckert & Ziegler SE WBO:EUZG
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eckert & Ziegler SE Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Eckert & Ziegler SE (WBO:EUZG) Overvalued in 2026?

Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued. The current stock price of €15.32 is trading 5.5% below its estimated GF Value™ of €16.21. GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.

Key valuation signals for WBO:EUZG:

  • Beta: N/A
  • GF Value™: €16.21 vs. price of €15.32 (5.5% below fair value)
  • GF Score™: 79/100

No single metric tells the full story. See the WBO:EUZG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eckert & Ziegler SE Business Description

Address Robert-Rossle-Street 10, Berlin, BB, DEU, 13125
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
79GF Score

Get the complete analysis for WBO:EUZG

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.32
Price
€16.21
GF Value